

gp120 Antibody
Catalog # ASC10755**Specification**

gp120 Antibody - Product Information

Application	WB
Primary Accession	Q6BBS3
Other Accession	AAB05604 , 1465781
Reactivity	Virus
Host	Goat
Clonality	Polyclonal
Isotype	IgG
Application Notes	Gp120 antibody can be used for detection of gp120 by Western blot at 1 µg/mL.

gp120 Antibody - Additional Information

Gene ID	155971
Target/Specificity	
env;	

Reconstitution & Storage

gp120 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.


Precautions


gp120 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

gp120 Antibody - Protein Information**gp120 Antibody - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

gp120 Antibody - Images



Western blot analysis of (A) 25 and (B) 100 ng of gp120 with gp120 antibody at 1 µg/mL.

gp120 Antibody - Background

gp120 Antibody: Human immunodeficiency virus type 1 (HIV-1) entry into target cells is directed by the envelope (Env) glycoproteins, which are present on the surface of HIV-1 virion or infected cells in the form of trimers consisting of gp120/gp41 complexes. The surface subunit, gp120, initiates the entry process by interacting sequentially with the CD4 receptor and a co-receptor CCR5 or CXCR4, thereby inducing a conformational change that allows the transmembrane (TM) gp41 subunit to mediate fusion between viral and target cell membranes. Cleavage of Env into its gp120 and gp41 components is necessary for activation of its fusogenic activity.

gp120 Antibody - References

Pinter A. Roles of HIV-1 Env variable regions in viral neutralization and vaccine development. *Curr. HIV Res.*2007; 5:542-53.

Alkhatib G and Berger EA. HIV coreceptors: from discovery and designation to new paradigms and promise. *Eur. J. Med. Res.*2007; 12:375-84.